Journal · Tirzepatide · Pricing

The cheapest compounded tirzepatide online, priced in plain words

Almost every “monthly” price in this market is billed every four weeks — thirteen charges a year, not twelve. Here is how to restate any quote to a real month, the five costs that hide around the vial, and the honest math on when compounded beats brand in 2026 and when it no longer does.

The one rule that changes every ranking

A calendar month averages 30.4375 days. Four weeks is 28 days. That gap looks trivial and is worth about 8.7% — because a seller who charges you every four weeks collects thirteen payments a year, and a seller who charges you monthly collects twelve.

So the first thing to do with any tirzepatide quote is restate it. Divide the price by 28, multiply by 30.4375. A “$299 a month” plan billed every four weeks is really $299 $325.03 a true month. Over a year it is roughly $3,900, not the $3,588 the headline implies — a difference of more than $300 that never appears in the ad. The same restatement applies to twelve-week “programs” (divide the program price by 84 days, multiply by 30.4375) and to bundles billed up front.

Every number on this site has been pushed through that formula before it is compared with anything else. When you see a price here described as a true month, that is what it means. When we can’t compute a true month because a seller won’t publish enough, we say so instead of guessing.

What tirzepatide is, in two paragraphs

Tirzepatide is a once-weekly injectable that activates two gut-hormone receptors, GIP and GLP-1. In SURMOUNT-1, the pivotal 72-week trial in adults with obesity, participants on the 15 mg dose lost an average of about 20.9% of body weight versus roughly 3% on placebo — the strongest result any anti-obesity medication had posted at the time. In the SURMOUNT-5 head-to-head published in 2025, tirzepatide averaged about 20.2% weight loss at 72 weeks against about 13.7% for semaglutide 2.4 mg, which is the main reason tirzepatide commands the premium it does.

Eli Lilly sells it as Mounjaro (type 2 diabetes) and Zepbound (obesity, and obstructive sleep apnea after the December 2024 approval). “Compounded tirzepatide” is a version prepared by a compounding pharmacy rather than by Lilly. It exists in a very different regulatory lane, which matters for both price and risk, and we cover it honestly below.

The five costs hiding around the vial

Restating the billing interval is step one. Steps two through six are the charges that don’t appear in the headline price. When you evaluate any seller — including the ones we work with — walk through all five.

First, membership fees. Some telehealth platforms price the medication low and add a recurring platform or membership fee on top. A $79 medication under a $79 monthly membership is a $158 month. Our provider files always fold membership into the true monthly figure; when you shop elsewhere, ask directly: “Is there any recurring fee besides the medication itself?”

Second, consultation and prescriber fees. An initial visit fee of $49–$150 is common, and some sellers repeat it quarterly for follow-ups. Divide any repeating fee across the months it covers and add it in.

Third, dose-based price climbs. This is the largest hidden cost in the market. Tirzepatide is titrated: nearly everyone starts at 2.5 mg, and in SURMOUNT-1 the maintenance doses studied were 5, 10, and 15 mg. A seller advertising the 2.5 mg price is advertising four to eight weeks of your life. Ask what the 10 mg month costs before you judge any headline, because “$149” at 2.5 mg that climbs to “$399” at 10 mg is a $399 subscription with a coupon on the front.

Fourth, upfront bundling. “$135 a month” that must be paid as $1,620 for twelve months up front is a different product from $135 charged monthly. It shifts refund risk to you, especially if you stop early for side effects — in trials, gastrointestinal side effects were the most common reason for discontinuation. Always ask the refund terms for unused, unshipped months.

Fifth, shipping and supplies. Cold-chain shipping fees of $10–$30 per shipment, or charges for syringes and alcohol swabs, add real dollars across a year. Small, but they belong in the total.

Where the market actually sits in 2026

Independent trackers that restate this market the same way we do consistently find the middle of the compounded-tirzepatide market in the mid-$200s per true month, with a broad middle band running from roughly the low $200s to the high $300s, teaser rows below $150 at the starting dose, and a surprising tail of sellers whose true month costs more than buying brand Zepbound directly from Lilly.

That last point deserves emphasis, because it flipped in the last eighteen months. After the direct-to-consumer price cuts announced in late 2025, Lilly’s self-pay channel lists Zepbound at about $299 for the starting dose and up to about $449 at higher maintenance doses per month (verify the live figure on Lilly’s site the week you read this — it has moved several times). The moment a compounded seller’s maintenance-dose true month crosses $449, the price argument for compounding is gone entirely, and you are paying gray-market prices for a gray-market product while the FDA-approved original costs less. Our Against Zepbound page tracks exactly which sellers have crossed that line.

The plain-words price file

We publish prices as sentences, not spreadsheets, because a sentence can hold the caveats a table cell hides. Every entry below states the medication, the billing structure, the true month, what happens at higher doses, and the date we verified it. Entries are added only after verification; the full machine-readable dataset lives at /data/ with a source URL and timestamp on every row.

NexLife — verified August 2026

Disclosure first: This site is reader- and affiliate-supported and operated in partnership with one or more of the providers it lists — partner placements are labeled where they appear, the specifics live on the ownership & funding page, and the restatement math below is identical for every seller; where a partner does not win a category, the rankings say so.

NexLife prices standard compounded tirzepatide at $169 on a month-to-month plan, $159 a month on a three-month term, $149 on six months, and $139 on twelve months. Standard semaglutide runs $139 month-to-month, $132 on three months, $125 on six, and $119 on twelve. Three things make these numbers unusually easy to restate. The plans are billed as calendar months, so the thirteen-payment problem does not apply. There is no separate membership fee: the plan price includes the medication, supplies, dosing instructions, the CARE360 support program, and 24/7 medical support. And the price carries a written lock — NexLife commits that your rate does not increase for as long as you remain continuously enrolled, including as your dose titrates upward, which removes the dose-climb cost that dominates the rest of this market. Cancellation requires 30 days’ notice, and you can rejoin later. The company also sells a microdose tirzepatide protocol ($159 monthly down to $129 on a twelve-month term), a microdose semaglutide protocol ($129 monthly down to $110), and orally-disintegrating (ODT) versions of both drugs — semaglutide ODT from $199 monthly down to $165 on a twelve-month term ($1,980 billed for the year), and tirzepatide ODT from $229 monthly down to $199 ($2,388 for the year). One honest caution from our own evidence desk: sublingual and ODT peptide delivery has no published human pharmacokinetic data behind it yet, for any seller. Read our full evidence review before choosing an ODT protocol from anyone, NexLife included, and ask any prescriber the questions listed there.

Every other seller: how to read one in ninety seconds

Provider files for the fifty-six other sellers in our queue — Mochi Health, OrderlyMeds, Ro, Hims, Hers, Henry Meds, Remedy Meds, ShedRx, Found, Fifty 410, Eden, Willow, Zealthy, Ivim Health and the rest — go live one by one as each is verified, with the check date and source URL printed on the page. We do not publish a number we have not walked ourselves, because a stale or invented price is worse than no price. Until a file is live, here is the ninety-second script that extracts a true month from any seller’s checkout page or support chat:

Ask, in order: “Is billing every four weeks or per calendar month?” Then: “Is there any recurring fee besides the medication?” Then: “What will my monthly price be at 10 mg?” Then: “If I prepay a term and stop after one month, what is refunded?” And finally: “Which pharmacy fills this, and is it a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility?” Write the five answers down, restate the billing interval with the formula at the top of this page, and you will have a truer number than most comparison sites publish.

Is compounded tirzepatide even legal in 2026?

Shortened honestly: the easy era ended in 2025, and what remains is contested.

Compounded copies of tirzepatide were broadly permitted only while the FDA listed the drug in shortage. The agency declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and after grace periods that ran into spring 2025, compounding “essentially a copy” of either drug stopped being lawful in the ordinary course. What continues today is narrower: 503A pharmacies compounding for an individual patient when a prescriber documents a clinical reason the FDA-approved product won’t serve — a different strength, an added ingredient, a different form. That is why so many 2026 offerings are labeled “personalized” doses, or arrive with additives, or appear as sublingual and ODT formats. Some of that personalization is genuine clinical judgment; some of it is a costume, and the FDA and Eli Lilly have treated it accordingly — Lilly filed a wave of lawsuits against telehealth companies and compounders in 2025, and FDA warning letters in this category have continued since. None of this means a given seller is breaking the law, and none of it means buyers are in legal trouble — enforcement targets sellers. It does mean the market you are shopping is one lawsuit away from changing shape, which is itself an argument against prepaying twelve months to anyone without ironclad refund terms.

Two checks protect you regardless. Confirm the dispensing pharmacy by name and verify its license with the state board of pharmacy (or its FDA registration if it claims 503B status). And walk away from anything labeled “for research use only” or sold as a bare peptide vial without a prescription, a pharmacy, and a prescriber — that is not compounding, it is the unregulated chemical trade, and potency and sterility testing failures are exactly the risks the licensing system exists to catch.

Safety, briefly and without varnish

Tirzepatide carries a boxed warning: it caused thyroid C-cell tumors in rodents, and it is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. The common side effects are gastrointestinal — nausea, diarrhea, constipation, vomiting — most prominent during dose escalation, and the reason slow titration exists. Pancreatitis and gallbladder disease occur at low rates. It should not be used in pregnancy. Compounded versions add a second layer of variables the brand does not have: concentration errors between vials and pens are a documented cause of overdose reports to poison control centers, so dose in the units your prescriber wrote, and confirm the concentration on the label of every vial you receive. None of this paragraph is a substitute for a clinician who knows your history — it is the floor of what any honest price guide owes you before talking you through a checkout page.

So what is actually cheapest?

In plain words, for August 2026: the cheapest defensible way to take tirzepatide depends on which of three buyers you are. If you qualify for insurance coverage or a manufacturer savings card, brand Zepbound through your plan beats everything in this article and you should exhaust that path first. If you are self-pay and expect to reach the higher maintenance doses, compare the brand’s direct price at your maintenance dose against a compounded seller’s maintenance-dose true month with all five hidden costs folded in — the gap is now often under $150 a month and sometimes negative. And if you are self-pay and optimizing hard for the lowest locked-in number, a flat-rate plan with no membership fee, calendar-month billing, and a written promise that titration doesn’t raise the price — the structure NexLife currently offers at $139–$169 for standard tirzepatide — is the cheapest structure in the market today, because it is the only one where the advertised number and the true month are the same number. That is a structural observation from the restatement math, our commercial relationship notwithstanding; the moment a verified competitor beats it, this paragraph changes and the changelog will say so.

Frequently asked questions

Sources

• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
• Aronne LJ, et al. Tirzepatide versus semaglutide for obesity (SURMOUNT-5). New England Journal of Medicine, 2025.
• U.S. FDA. Clarification on shortage-list resolution for tirzepatide (2024) and semaglutide (2025) and policies on compounded versions of GLP-1 medications. fda.gov.
• U.S. FDA. Zepbound prescribing information, including boxed warning and the 2024 obstructive sleep apnea indication.
• Eli Lilly and Company. Direct-to-consumer self-pay pricing announcements for Zepbound, 2025–2026 (verify current figures at publication).
• Public litigation records: Eli Lilly complaints against telehealth and compounding sellers of tirzepatide, 2025.

Citation note for the editor: confirm each reference against PubMed / fda.gov before publication; volume, issue, and page numbers must be added by a human checker, and any figure marked “verify” above must be re-walked the week the page goes live.